Blindness News and Research

RSS

Ampio completes partial planned interim review in Optina trial for diabetic macular edema

Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane completed two phase III studies, Ampion-completed proof of concept studies and Optina), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina trial for diabetic macular edema.

19 Mar 2012

ThromboGenics, Alcon collaborate to commercialize ocriplasmin outside the US

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.

16 Mar 2012

Bayer HealthCare receives FDA approval for Natazia to treat HMB

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the treatment of heavy menstrual bleeding (HMB) that is not caused by any diagnosed conditions of the uterus (womb), in women who choose an oral contraceptive (OC) for contraception.

15 Mar 2012

Scientists grow rudimentary retina structure from blood cells

For the first time, scientists at the University of Wisconsin-Madison have made early retina structures containing proliferating neuroretinal progenitor cells using induced pluripotent stem (iPS) cells derived from human blood.

14 Mar 2012

Positive results from Bausch + Lomb, NicOx BOL‑303259‑X phase 2b study on OAG

Bausch + Lomb, the global eye health company, and NicOx S.A. today announced positive top-line results from the phase 2b study conducted with BOL‑303259‑X, a novel nitric oxide-donating prostaglandin F2‑alpha analog, in patients with open-angle glaucoma or ocular hypertension.

13 Mar 2012

Connect during MS Awareness Week

Multiple sclerosis is a life altering disease that affects each person in a unique and different way. MS destroys connections, divides minds from bodies, pulls people from their lives and away from one another. Therefore, it's only fitting that connections would be its greatest enemy.

12 Mar 2012

Two scientists receive The Brain Prize 2012 for pioneering work on hearing and deafness

The Grete Lundbeck European Brain Research Foundation announced today that The Brain Prize 2012 is jointly awarded to Christine Petit and Karen Steel.

12 Mar 2012

Chlamydia has evolved more actively than previously thought

In a study released today in Nature Genetics, researchers have found that Chlamydia has evolved more actively than was previously thought. Using whole genome sequencing the researchers show that the exchange of DNA between different strains of Chlamydia to form new strains is much more common than expected.

12 Mar 2012

Researchers produce extensive catalog of genes expressed in human islets

A new JDRF-funded study shows that many of the genes known to play a role in type 1 diabetes (T1D) are expressed in pancreatic beta cells, suggesting that the cell responsible for producing insulin may be playing a part in its own destruction to lead to T1D.

12 Mar 2012

Genetically modified pig may hold keys to develop treatments for RP

A newly developed, genetically modified pig may hold the keys to the development of improved treatments and possibly even a cure for retinitis pigmentosa (RP), the most common inherited retinal disease in the United States.

9 Mar 2012

Ugandan government draws up response plan to combat 'nodding disease'

The Ugandan government is creating a "wide-ranging response plan" to "nodding disease, a mysterious ailment characterized by seizures, nodding of the head, mental retardation and stunting, which affects thousands of children in northern Uganda," IRIN reports.

8 Mar 2012

Study suggests onchocerciasis can be eliminated with sustained distribution of treatment

"New research supported by Sightsavers and the African Programme for Onchocerciasis Control (APOC) shows that yes, onchocerciasis really can be eliminated when treatment is distributed in an area for a sustained period" and "found that the disease may already be eliminated in one Nigerian state, marking a significant milestone for onchocerciasis control programs," the Global Network for Neglected Diseases' "End the Neglect" blog writes.

8 Mar 2012

Australian TGA approves Bayer's EYLEA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has received approval from the Australian Therapeutic Goods Administration (TGA) for EYLEA (aflibercept) Injection for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD) at a recommended dose of 2 milligrams (mg) via intravitreal injection per month for three consecutive months, followed by 2 milligrams via intravitreal injection every two months.

8 Mar 2012

Some top researchers no longer think of glaucoma solely as an eye disease

A new paradigm to explain glaucoma is rapidly emerging, and it is generating brain-based treatment advances that may ultimately vanquish the disease known as the "sneak thief of sight." A review now available in Ophthalmology, the journal of the American Academy of Ophthalmology, reports that some top researchers no longer think of glaucoma solely as an eye disease.

8 Mar 2012

Report highlights benefits of Nuvilex's cell encapsulation technology for diabetes

Nuvilex, Inc., an emerging biotechnology provider of cell and gene therapy solutions, today provided additional details based on the Goldman Small Cap Research report issued February 29, 2012, that highlighted the company's cell encapsulation technology and its benefits for treating chronic diseases such as diabetes.

2 Mar 2012

People with TBI show decline in financial management skills

People who experience a traumatic brain injury show a marked decline in the ability to make appropriate financial decisions in the immediate aftermath and a continued impairment on complex financial skills six months later, according to new research from the University of Alabama at Birmingham.

29 Feb 2012

Dompé enters definitive agreement to acquire Anabasis

Dompé, one of Italy's leading biopharmaceutical companies, announced today that it has entered into a definitive agreement to acquire 100% of Anabasis Srl, a privately held Italian research and development biopharmaceutical company, focused on ocular diseases.

28 Feb 2012

Eradication of river blindness in Africa is feasible

In this AlertNet opinion piece, Simon Bush, director of neglected tropical diseases (NTDs) at Sightsavers, an international NGO helping people with visual impairments in developing countries, examines efforts to rid Africa of onchocerciasis -- a blinding NTD.

24 Feb 2012

First comprehensive framework to close the gap on Indigenous eye health for Australians

Presently Indigenous Australians suffer six times the blindness of mainstream Australians and 94 percent of vision loss in Indigenous Australians is unnecessary, preventable or treatable.

24 Feb 2012

Wolters Kluwer, APAO launch Asia-Pacific Journal of Ophthalmology

Wolters Kluwer Health and the Asia-Pacific Academy of Ophthalmology (APAO) are pleased to announce the launch of the Asia-Pacific Journal of Ophthalmology.

24 Feb 2012